IMMUNOGEONOMICS AND FLOW CYTOMETRY SHARED RESOURCE The Immunogenomics and Flow Cytometry SR (IMCF) is a hybrid core that provides access to state-of-the-art techniques such as mass cytometry and immunogenomics analysis of bulk and single cell next generation sequencing data coupled with a high utilization Flow Cytometry facility with a 30-year LCCC history. New immune monitoring capabilities were developed in response to investigator needs, particularly for the analysis of immune responses in preclinical tumor models and human clinical research. The immunogenomics component offers a full suite of immunogenomics techniques, including immune gene signature and pathway analysis, cell phenotype deconvolution, MHC haplotype prediction, neoantigen prediction, T cell and B cell repertoire profiling, and systems level analyses such as cytokine network analysis and integrated survival modeling. This is joined by an investment in CyTOF for expanded panel analysis of cellular phenotypes. This component currently supports correlative science for tissues being collected from eight immunotherapy trials and multiple in vivo animal models of cancer. In addition to these new capabilities, the facility also houses a full complement of highly used analytic flow cytometers and cell sorters for both mouse and human work, New purchases in addition the CyTOF are two new spectral analytic machines. Most important for the research community, all SR components have expert staff to support investigators in experimental design, sample processing, data acquisition, and downstream analysis. IMCF is led by Dr. Vincent, MD, an expert in immunogenomics and Dr. Fisher, PhD who has led the LCC Flow facility since 2010 and has over 30 years? experience in flow cytometry. The budget requested ($211,126) is a small proportion of the total operating budget of $1.7M. Flow cytometry is a traditionally heavily used facility; 80 members were users in fiscal year 2019.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089827
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, V├ęsteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications